TP53 and prostate carcinoma: Taking flubendazole as an example, the FDA-approved anthelmintic drug has been found to downregulate the expression of SLC7A11 and GPX4 in a targeted manner to p53, activating ferroptosis and exerting the anti-proliferative and pro-apoptotic effects in castration-resistant prostate cancer [67].